Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the …
Posted by admin | Filed under Compulisve Disorders Support, Compulsive Disorders, Compulsive Disorders Treatment, Obsessive Compulsive
More info…
NEW YORK & BUDAPEST, Hungary–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and …
Leave a Reply
You must be logged in to post a comment.